Conference to be Held November 6-9, 2014 in National Harbor, MD.
Company Website:
http://www.pvct.com
KNOXVILLE, Tenn. -- (Business Wire)
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company
(“Provectus”), announced today that a team of researchers led by Shari
Pilon-Thomas, PhD from the Moffitt Cancer Center will present data at
the Society for Immunotherapy of Cancer [SITC] 29th Annual
Meeting with an abstract titled “Efficacy of Intralesional Injection
with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model
of Melanoma.”
Dr. Craig Dees, PhD, CEO of Provectus, said, "Medical oncologists are
interested in potential combinations of PV-10 with immune checkpoint
inhibitors for patients with significant tumor burden inaccessible to
intralesional injection. Dr. Pilon-Thomas’s work is an important step
forward as part of our corporate strategy for addressing unmet need in
late stage melanoma patients.”
PV-10, a 10% solution of Rose Bengal that is currently being examined as
a novel cancer therapeutic, is designed to selectively target and
destroy cancer cells without harming surrounding healthy tissue,
minimizing potential for systemic side effects.
About The Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3)
non-profit society of medical professionals. Recent advances in
immunology and biology have opened up new horizons in the field of
cancer therapy, with an upsurge in the integration of new biologic
agents into clinical practice. With several high-caliber scientific
meetings with a focus on clinical and translational aspects of biologic
approaches to cancer treatment and numerous networking opportunities
unique to this organization, the Society for Immunotherapy of Cancer
(SITC) has developed into the premier destination for interaction and
innovation in the cancer immunology and immunotherapy community. The
goals of SITC are directed towards the rapid dissemination of
information in these areas to expedite the safe transfer of both basic
and applied research to the clinical setting.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug for
cancer, is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has completed
phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of
PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company’s other clinical trials can be
found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company’s
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains “forward-looking
statements” as defined under U.S. federal securities laws. These
statements reflect management’s current knowledge, assumptions, beliefs,
estimates, and expectations and express management’s current views of
future performance, results, and trends and may be identified by their
use of terms such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2013, and in our Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2014, and June 30,
2014), and the following:
|
•
|
|
our determination, based on guidance from the FDA, whether to
proceed with or without a partner with a phase 3 trial of PV-10 to
treat locally advanced cutaneous melanoma and the costs associated
with such a trial if it is necessary;
|
|
•
| |
our determination whether to license PV-10, our melanoma drug
product candidate, and other solid tumors such as liver cancer, if
such licensure is appropriate considering the timing and structure
of such a license, or to commercialize PV-10 on our own to treat
melanoma and other solid tumors such as liver cancer;
|
|
•
| |
our ability to license our dermatology drug product candidate,
PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis
results, which are in the process of being further developed in
conjunction with mechanism of action studies; and
|
|
•
| |
our ability to raise additional capital if we determine to
commercialize PV-10 and/or PH-10 on our own, although our
expectation is to be acquired by a prospective pharmaceutical or
biotech concern prior to commercialization.
|
Contacts:
Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, CFO, COO,
866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Investor
Relations
Marlon Nurse, DM, SVP, 212-564-4700
or
Media
Relations
Bill Gordon, 212-724-6312
Source: Provectus Biopharmaceuticals, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.